Amaryl

This page contains recent news articles, when available, and an overview of Amaryl but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.


Overview:

Amaryl
(when available)

Pharmacology and use:
Glimepiride, like glyburide and glipizide, is a "second-generation" sulfonylurea agents. Glimepiride is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin. For concomitant use with insulin for the treatment of noninsulin-dependent (Type II) diabetes mellitus; For the treatment of hyperglycemia that cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic agent

Mechanism Of Action:
The mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glimepiride likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.

News Articles on Glimepiride

Chason found not guilty in murder trial  -  ‎Dec 9, 2009‎
He died April 23, and tests showed he had the diabetes drug glimepiride in his system, which is marketed under the brand name Amaryl. ... Jackson Sun

Health Brief: December 11  -  ‎Dec 11, 2009‎
Some brand names under that umbrella are Dymelor, Amaryl, and Glynase. Experts say diabetic seniors taking those drugs had more heart problems and a higher ... WBAY

Sanofi may take Zealand Pharma stake-Les Echos  -  ‎Dec 23, 2009‎
Sanofi is seeking to broaden its diabetes offering, which includes blockbuster insulin Lantus, Apidra and Amaryl, and has set up a diabetes division with ... Reuters

Lại kê khai Ä‘iá»?u chỉnh tăng giá thuốc  -  ‎Dec 18, 2009‎
Trong đó, 9 mặt hàng đã áp dụng vào cuối tháng 11-2009, 7 mặt hàng còn lại sẽ áp dụng vào tháng 1-2010 gồm: Amaryl 2mg, Amaryl 4mg, Co-Amaryl 2mg, ... Sài gòn Giải Phóng

Biotech : Novartis acquiert Corthera, Sanofi-Aventis convoite Zealand  -  ‎Dec 23, 2009‎
Sur ce segment, le laboratoire détient déjà l'insuline Lantus (blockbuster dont le brevet expire en 2014), l'Apidra et l'Amaryl, ainsi qu'un produit en ... L'Usine Nouvelle

常用的糖尿病藥物與心衰竭有關  -  ‎Dec 10, 2009‎
...研究中探討的第2代磺醯尿素類藥物包括:glipizide (商å“?å??Glucotrol)ã€?gliclazideã€?glimepiride (商å“?å??Amaryl)以å?Šglyburide (商å“? ... 臺灣新浪網

Brand Name: Amaryl  -  ‎Nov 11, 2009‎
Amaryl (generic name: glimepiride; brand names include: Diapride / Amyline / Euglim) is an oral anti-diabetic medicine of the sulfonylurea class. ... Pattaya Daily News

Milpitas homes in October sell for average of $394000  -  ‎Nov 4, 2009‎
...$226000, 10-14-09 [3 bdms/1597 sqft/1955 year built], Previous Sale 05-06-1988, $163000 2598 Amaryl Drive - D. & T. Saga to N. & A. Uychoco, $420000, ... San Jose Mercury News

Sanofi-aventis Delivers a Solid Performance in Third Quarter 2009  -  ‎Oct 30, 2009‎
Tritace(R) 73 -6.2% 34 -2.8% ----------------- ------ --------- ------ --------- -------- --------- Amaryl(R) 20 0.0% 1 0.0% 82 7.4% ... Reuters

Brand Names/Synonyms:
Amaryl is also known by the following brand names and/or synonymsAmarel; Amaryl; CCRIS 7083; CHEMBANK1624; Endial; Glimepirid; Glimepirida [Spanish]; Glimepiride; Glimepiride [Usan:Ban:Inn]; Glimepiridum [Latin]; Glimepride; HOE 490

Drug Category:
Amaryl is categorized under the following by the FDA: Immunosuppressive Agents; Hypoglycemic Agents; Antiarrhythmic Agents; Sulfonylureas; ATC:A10BB12

Dosage Forms:
Oral tablets with various strengths

Absorption:
completely (100%) absorbed

Interactions:
[an error occurred while processing this directive]



Chemical IUPAC Name:
3-ethyl-N,N-bis(3-ethyl-4-methyl-2-oxo-5H-pyrrol-2-yl)-4-methyl-2-oxo-5H-pyrrole-1-carboxamide





Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy